Chiesi signs $1.9B deal to acquire KalVista and its approved drug

Article

Chiesi signs $1.9B deal to acquire KalVista and its approved drug

Source

Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...

Tweets, videos, filings, articles, and source pages tied to this read.

1
endpoints.newsendpoints.news